Today: 29 June 2026
HSBC share price holds near 1,290p as results loom — what traders are watching
23 February 2026
1 min read

HSBC share price holds near 1,290p as results loom — what traders are watching

London, February 23, 2026, 08:19 GMT — Regular session

London-listed HSBC Holdings shares hovered at 1,290 pence in early Monday trade. Over in Hong Kong, the stock edged up nearly 1% to HK$135.70. The ADR wrapped up the last New York session at $88.15, up roughly 1.5%, according to HSBC’s investor site.

Investors now turn their attention to Wednesday, with HSBC set to announce its 2025 annual results at 4 a.m. GMT. The bank’s results page notes an investor and analyst meeting will follow later that morning.

A regulatory filing indicates a board committee will gather on Feb. 25 to review final results and discuss the possibility of issuing a fourth interim dividend for 2025. Should the board give the green light, shareholders on record as of March 13—including ADS holders in New York—would see payment on April 30.

Currency markets wrestled with renewed U.S. trade-policy uncertainty after the Supreme Court tossed out several of President Donald Trump’s tariffs. The dollar dipped, and Trump fired back by slapping a sweeping 15% tariff on all imports, Reuters said. “It weakens the dollar in the sense that it potentially benefits non-U.S. growth,” OCBC Bank’s Sim Moh Siong told Reuters from Singapore. Reuters

HSBC’s eyes, right now, are on earnings quality, not just the top-line figure. Investors will be digging into the portion of profit driven by interest income, tracking cost growth, and watching for any bigger push into wealth fees as funding expenses begin to level out.

Net interest income matters here — that’s the spread between what banks make from loans and what they shell out on deposits. This line item usually shrinks as rates dip, or if banks are driven to raise deposit rates to hold on to customer funds.

HSBC’s numbers are a tricky read. The bank reports in dollars, but much of its business is rooted in Hong Kong and the UK. It’s also heavily tied to trade flows that can shift sharply with policy headlines, rather than just by what central banks do.

Capital decisions might weigh just as heavily as revenues here. Investors will be watching for a clear dividend roadmap or hints at buybacks—anything less, after the stock’s recent surge, and the mood could sour quickly if guidance disappoints.

Plenty could trip this up. A guarded forecast, beefed-up credit-loss reserves, or even a suggestion that capital returns might face limits—any of that could weigh on the stock, particularly if markets swing back to risk-off mode.

According to Investing.com’s earnings calendar, HSBC will deliver its report on Feb. 25. For traders, that’s at least one concrete catalyst in a week when bank stocks are likely to be moved by headlines.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • SHO.PRH Yield Tops 7% as Stock Drops, Discount Narrows
    June 29, 2026, 3:47 PM EDT. Shares of Sunstone Hotel Investors' 6.125% Series H Cumulative Preferred Stock (SHO.PRH) paid a yield of over 7% on Wednesday, with quarterly dividends annualized at $1.5313 and the stock trading down to $21.73. That puts the yield near the 7.96% average across real estate preferreds. SHO.PRH was priced at an 11.76% discount to liquidation value, tighter than the category's typical 14.88% markdown. SHO.PRH slipped 0.1% while Sunstone common jumped 3.2% for the day. Investors still picked up the fixed payout, which can be a draw during choppy trading in real estate stocks.
Johnson & Johnson stock falls on DePuy sale talk — what to watch next for JNJ shares
Previous Story

Johnson & Johnson stock falls on DePuy sale talk — what to watch next for JNJ shares

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Next Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Go toTop